CRISPR breakthrough: new 'Off-the-Shelf' cell therapy fights tough blood cancers
NCT ID NCT05643742
Summary
This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main goals are to find a safe dose and see how well the treatment works in about 120 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Royal Prince Alfred
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
SCRI
RECRUITINGSan Antonio, Texas, 78229, United States
-
Sir Charles Gairdner Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
-
University of Kansas
RECRUITINGWestwood, Kansas, 66205, United States
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.